Bulk Inquiry
LDK 378
- Ceritinib
Axon 2224
CAS:
1032900-25-6
Purity:
99%
- Soluble in 0.1N HCl(aq) and DMSO
- MF: C28H36ClN5O3S
- MW: 558.14
Description
Potent, bioavailable, and selective anaplastic lymphoma kinase (ALK) inhibitor (IC50 value 0.2 nM) with >35 fold selectivity over InsR, IGF-1R. LDK 378 induced a dose-dependent tumor growth inhibition and tumor regression in multiple rat xenograft models.
More Information
| Parent CAS No. | 1032900-25-6 |
|---|---|
| Chemical Name | 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine |
| SMILES | C1(NC2=CC(C)=C(C3CCNCC3)C=C2OC(C)C)=NC=C(Cl)C(NC2=CC=CC=C2S(C(C)C)(=O)=O)=N1 |
| MFCD | N.A. |
| InChi | InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34) |
| InChiKey | VERWOWGGCGHDQE-UHFFFAOYSA-N |
| CID | 57379345 |
| Short Description | ALK inhibitor |
References
- J. Chen et al. LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. J. Med. Chem. 2013, 56, 5673-5674.
- T.H. Marsilje et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(...). J. Med. Chem. 2013, 56, 5675-5690.
- E. Ardini et al. ALK Inhibitors, a Pharmaceutical Perspective. Front Oncol. 2012, 2, 17.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1416 | NVP-TAE684 |
From $55.00 |
| 1660 | Crizotinib |
From $88.00 |
| 1884 | Alectinib |
From $77.00 |
| 2005 | ASP 3026 |
From $88.00 |
| 2153 | AZD3463 |
From $115.50 |
| 2267 | GSK 1838705A |
From $121.00 |
| 2294 | KRCA 0008 |
From $104.50 |
| 2600 | PF 06463922 |
From $115.50 |
| 2978 | Brigatinib |
From $88.00 |
| 3866 | TAE226 |
From $121.00 |
| 3931 | CEP-28122 |
From Inquiry |
Other Categories
Get a Quote for
Loading...